Valuation: Sarepta Therapeutics, Inc.

Market Cap 1.97B 1.76B 1.61B 1.47B 2.75B 187B 2.81B 19.21B 7.75B 98.31B 7.38B 7.22B 311B P/E 2026 *
6.26x
P/E 2027 * 81.3x
Enterprise Value 1.72B 1.54B 1.41B 1.28B 2.41B 163B 2.46B 16.83B 6.79B 86.1B 6.46B 6.33B 272B EV / Sales 2026 *
0.94x
EV / Sales 2027 * 0.98x
Free-Float
94.53%
Yield 2026 *
-
Yield 2027 * -
1 day-1.61%
1 week+3.33%
Current month-1.61%
1 month+4.27%
3 months+23.28%
6 months-14.75%
Current year-14.87%
1 week 17.69
Extreme 17.69
19.68
1 month 16.37
Extreme 16.3675
19.7
Current year 14.68
Extreme 14.68
24.68
1 year 14.68
Extreme 14.68
24.68
3 years 10.42
Extreme 10.415
173.25
5 years 10.42
Extreme 10.415
173.25
10 years 10.42
Extreme 10.415
181.83
Manager TitleAgeSince
Chief Executive Officer 60 2026-07-27
Director of Finance/CFO 47 2025-07-15
Director of Finance/CFO 50 2020-12-13
Director TitleAgeSince
Chairman 73 2015-04-15
Director/Board Member 87 2010-05-31
Director/Board Member 67 2015-06-01
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Tax

Chief Financial Officer

-13,272 0.0126%
9/4/26 Tax

General Counsel

-22,025 0.0209%
9/4/26 Tax

Chairperson

-24,799 0.0235%
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%+3.33%-23.70%-76.06% 1.97B
-0.46%+10.80%+63.52%+154.48% 1,263B
-0.97%+2.56%+43.25%+81.96% 658B
-2.05%+1.12%+32.47%+102.74% 521B
-1.54%+1.61%+53.42%+67.10% 391B
-0.78%+2.13%+72.55%+44.25% 369B
-1.69%+2.75%+32.49%+54.35% 307B
-0.72%+8.08%+11.15%+34.09% 290B
-0.12%+5.96%+55.97%+78.44% 252B
-0.21%+9.16%+42.19%+112.41% 212B
Average -0.76%+5.81%+38.33%+65.38% 426.39B
Weighted average by Cap. -0.65%+6.60%+49.11%+97.34%

Financials

2026 *2027 *
Net sales 1.83B 1.64B 1.5B 1.37B 2.56B 174B 2.62B 17.9B 7.22B 91.58B 6.87B 6.73B 289B 1.38B 1.23B 1.13B 1.03B 1.93B 131B 1.97B 13.49B 5.44B 69.02B 5.18B 5.07B 218B
Net income 340M 304M 278M 253M 475M 32.23B 486M 3.32B 1.34B 16.98B 1.27B 1.25B 53.65B -6.15M -5.5M -5.03M -4.59M -8.6M -583M -8.79M -60.04M -24.23M -307M -23.06M -22.57M -971M
Net Debt -244M -218M -200M -182M -342M -23.18B -349M -2.39B -963M -12.21B -917M -897M -38.59B -618M -552M -506M -461M -864M -58.6B -883M -6.03B -2.43B -30.87B -2.32B -2.27B -97.54B
Projected Income Statement - Annual - Sarepta Therapeutics, Inc.
Logo Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
Employees
835
Date Price Change Volume
26-11-02 US$18.32 -1.61% 1,158,833
26-10-30 US$18.62 -3.17% 1,318,156
26-10-29 US$19.23 -0.47% 1,188,091
26-10-28 US$19.32 +2.28% 1,356,734
26-10-27 US$18.89 +5.06% 2,226,641
Trader
Investor
Global
Quality
ESG MSCI
B
MarketScreener Ratings - Sarepta Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
18.62USD
Average target price
21.64USD
Spread / Average Target
+16.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sarepta Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SRPT Stock